Lapatinib Withdrawn Phase 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00343759Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
NCT01005641ELBA: Exemestane and Lapatinib in Advanced Breast Cancer